Hints and tips:
...US pharmaceutical Abbott Laboratories also on Thursday announced a $25bn deal for St Jude Medical, while France’s Sanofi earlier today went public with the details of an unsolicited bid for San Francisco-based...
...Shares of AbbVie, which was spun off from Abbott Laboratories in 2013, fell as much as 8 per cent following its pre-market release of third-quarter earnings....
...A trio of deals worth a combined $45bn breathed fresh life into the healthcare mergers and acquisitions boom on Thursday as Abbott Laboratories, AbbVie and Sanofi all went shopping for assets....
...The company was spun off from Abbott Laboratories last year....
...Touting the appeal of AbbVie stock to Shire shareholders, Mr González highlighted that the company’s market capitalisation was now greater, at $86bn, than the entire value of Abbott Laboratories before its...
...AbbVie, spun-off from Abbott Laboratories last year, derives almost 60 per cent of sales from its Humira rheumatoid arthritis drug, which loses patent protection at the end of 2016....
...For AbbVie, which was only created last year when Abbott Laboratories split its pharmaceuticals unit off – buying Shire would diversify its drug pipeline and allow it to access billions of dollars in foreign...
...The Chicago-based company was spun off from Abbott Laboratories last year....
...Richard Gonzalez, the current chief operating officer who will take over the pharmaceutical business, said his company would acquire a proportion of Abbott’s $16bn group debt, although he did not say how...
...And there’s Johnson v. Johnson, her story of the court battle surrounding J. Seward Johnson’s $500m will, and her novel The Straw Man....
International Edition